Bad Blood of Theranos
Theranos, the biotech startup that once promised revolutionary blood test technologies to the world, came to an end after evidence of its fraud finally came to bear. Journalist John Carreyrou unravels the rise and downfall of the company, once valued at $9B, in his book Bad Blood: Secrets and Lies in a Silicon Valley Startup. This post summarises a few factors that enabled Theranos’ rise, and several red flags that warranted greater scrutiny from cautious investors (in hindsight). Continue Reading …